Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

Zhang Y, Mun SR, Linares JF, Ahn JW, Towers CG, Ji CH, et al. ZZ-dependent regulation of p62/SQSTM1 in autophagy. Nat Commun. 2018;9(1):4373.

D'Alfonso TM, Subramaniyam S, Ginter PS, Mosquera JM, Croyle J, Liu Y-, et al. Characterization of CD34-deficient myofibroblastomas of the breast. Breast J. 2018;24(1):55-61.

Bandini C, Pupuleku A, Spaccarotella E, Pellegrino E, Wang R, Vitale N, et al. IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas. Cancers (Basel). 2018;10(1).

Lu X, Fernando TM, Lossos C, Yusufova N, Liu F, Fontan L, et al. PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival. Blood. 2018;132(19):2026-2039.

Ahirwar DK, Nasser MW, Ouseph MM, Elbaz M, Cuitiño MC, Kladney RD, et al. Fibroblast-derived CXCL12 promotes breast cancer metastasis by facilitating tumor cell intravasation. Oncogene. 2018;37(32):4428-4442.

Goyal A, Sharaiha RZ, Alperstein SA, Siddiqui MT. Cytologic diagnosis of adenocarcinoma on bile duct brushings in the presence of stent associated changes: A retrospective analysis. Diagn Cytopathol. 2018;46(10):826-832.

Lange KR, Fischer C, Rajappa P, Connors S, Pisapia D, Greenfield JP, et al. Rapid autopsy of a patient with recurrent anaplastic ependymoma. Palliat Support Care. 2018;16(2):238-242.

Cybulska P, Goss C, Tew WP, Parameswaran R, Sonoda Y. Corrigendum to "Indications for and complications of transfusion and the management of gynecologic malignancies" [Gynecol. Oncol. 146 (2017) 416-426]. Gynecol Oncol. 2018;148(1):235.

Snodgrass R, Gardner A, Semeere A, Kopparthy VL, Duru J, Maurer T, et al. A portable device for nucleic acid quantification powered by sunlight, a flame or electricity. Nat Biomed Eng. 2018;2(9):657-665.

Nowinski S, Santaolalla A, O'Leary B, Loda M, Mirchandani A, Emberton M, et al. Systematic identification of functionally relevant risk alleles to stratify aggressive versus indolent prostate cancer. Oncotarget. 2018;9(16):12812-12824.